Readily available biomarkers predict poor survival in metastatic pancreatic cancer

  • M. Strijker (Creator)
  • Eran van Veldhuisen (Contributor)
  • Lydia G. van der Geest (Contributor)
  • Olivier R. Busch (Creator)
  • M. F. Bijlsma (Creator)
  • Nadia Haj Mohammad (Contributor)
  • Marjolein Y. Homs (Creator)
  • Jeanin E. van Hooft (Contributor)
  • Joanne Verheij (Creator)
  • J. M.P.G.M. de Vos-Geelen (Contributor)
  • Johanna W. Wilmink (Creator)
  • W. Ewout W. Steyerberg (Contributor)
  • Marc G. Besselink (Creator)
  • Hanneke van Laarhoven (Contributor)
  • Olivier R.C. Busch (Creator)
  • Johanna W. Wilmink (Creator)
  • Marc G. Besselink (Creator)
  • Hanneke W Van Laarhoven (Creator)



Identification of metastatic pancreatic cancer (mPC) patients with the worst prognosis could help to tailor therapy. We evaluated readily available biomarkers for the prediction of 90-day mortality in a nationwide cohort of mPC patients. Patients with s...
Date made available2021
PublisherTaylor & Francis

Cite this